天津华域药业

天津华域药业有限公司 (Tianjin Huayu Pharmaceutical) is a Chinese biotechnology company founded in 2021 and based in Tianjin. As a wholly-owned subsidiary of Sino Biotech (华域生物), the company focuses on the research, development, and manufacturing of cell therapy products, particularly off-the-shelf mesenchymal stem cell therapies. Its lead program, an human umbilical cord mesenchymal stem cell injection, received Investigational New Drug (IND) approval from the NMPA in 2025 and is currently in Phase 1 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF). Additionally, the company is advancing clinical research for chronic obstructive pulmonary disease (COPD) under the national dual-备案 system. Operating within a state-of-the-art GMP-compliant facility, Tianjin Huayu Pharmaceutical aims to provide scalable and accessible regenerative medicine solutions.